Johnson & Johnson Fails to Flip Missouri Verdict on Massive Talc Lawsuit
Struck a blow in Missouri, Johnson & Johnson couldn’t get the state’s trial judge to reverse a staggering US$4.69 billion award to 22 women who blamed ovarian cancer on asbestos‑infused talc in the company’s famous Baby Powder.
Why the Court Refused to Budge
- Judge Rex Burlison ruled that the jury’s punishment was justified by what he called the company’s “particularly reprehensible conduct.”
- The plaintiffs presented enough evidence to support the jury’s decision, so the motion to set aside was denied.
- J&J’s statement: “This was just a procedural step—our real aim? We’re confident the verdict will be overturned on appeal.”
The Back‑story: A Long‑Running Tantalum of Talc
For decades, the women and families argue that daily use of Baby Powder and other talc products set the stage for their cancer. They claim J&J knew of asbestos contamination since the 1970s but never warned consumers.
Meanwhile, lawsuits have shifted from accusing talc itself of causing ovarian cancer to alleging that asbestos‑laden talc triggers the same deadly disease and mesothelioma—a cancer closely linked to asbestos exposure.
J&J’s Defiant Line
The company insists its talc has never contained asbestos, citing decades of studies and regulatory checks that back its safety. They also argue that most of the plaintiffs are out‑of‑state and thus lack standing to sue in Missouri.
Despite these arguments, Judge Burlison kept the case in the state’s court because of J&J’s clear connection to Missouri.
Market Fallout
- Reuters’ special report last Friday exposed company documents that sent shares nosediving.
- J&J shares fell over 13% since then, wiping out more than US$45 billion in market value.
- On Wednesday, the stock was down roughly 2% at $127.88.
Current Verdict Breakdown
- Compensatory damages: US$550 million
- Punitive damages: US$4.14 billion
- Total: US$4.69 billion
Perspective from the Lawyer
Mark Lanier, the women’s attorney who defended the case, said the plaintiffs were delighted at judge Burlison’s decision and emphasized their confidence in the appeal’s success.
What’s Next?
With the verdict now set aside denied, J&J is poised for a higher‑court showdown—while the large jury award remains a bellwether of how companies can be held liable for product risks.
